Združene države Amerike - angleščina - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection, usp is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine [see warnings and precautions (5.7)] pregnancy category c. animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if cle

Združene države Amerike - angleščina - NLM (National Library of Medicine)

mylan institutional llc - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine is contraindicated in patients with: pregnancy category c . animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine can cause fetal harm when administered to pregnant women, adenosine should be used during pregnancy only if clearly needed. it is not known whether adenosine is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine in nursing infants, the decision to interrupt nursing after administration of adenosine or not to administer adenosine, should take into account the importance of the drug to the mother. the safety and effectiveness of adenosine in patients less than 18 years of age have not been established. clinical studies with adenosine did not include suffic

Združene države Amerike - angleščina - NLM (National Library of Medicine)

wockhardt usa llc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration.  it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ).1 adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.  in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functio

Združene države Amerike - angleščina - NLM (National Library of Medicine)

wockhardt limited - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration.  it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ).1 adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.  in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functio

Združene države Amerike - angleščina - NLM (National Library of Medicine)

agila specialties private limited - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

wellstat therapeutics corporation - uridine triacetate (unii: 2wp61f175m) (uridine - unii:whi7hq7h85) - uridine triacetate 951 mg in 1 g - xuriden® is indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. none risk summary there are no available data on xuriden use in pregnant women to inform a drug-associated risk. when administered orally to pregnant rats during the period of organogenesis, uridine triacetate at doses similar to the maximum recommended human dose (mrhd) of 120 mg/kg per day was not teratogenic and did not produce adverse effects on embryo-fetal development [see data] . the background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data in an embryo-fetal development study, uridine triacetate was administered orally to pregnant rats during the period of organogenesis at doses up to 2000 mg/kg per day (about 2.7 times the maximum recommended human dose (mrhd) of 120

Združene države Amerike - angleščina - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribavirin capsules in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis c (chc) in patients 3 years of age and older with compensated liver disease [see warnings and precautions (5.9, 5.10) , and use in specific populations (8.4) ]. the following points should be considered when initiating ribavirin combination therapy with peginterferon alfa-2b or interferon alfa-2b: ribavirin combination therapy is contraindicated in: pregnancy category x [see contraindications (4), warnings and precautions (5.1), and nonclinical toxicology (13.1) ]. treatment and posttreatment potential risk to the fetus ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. it is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. in a study in rats, it was concluded that dominant lethality was not induced by ribavirin at doses up to 200 mg/kg for 5 days (estimat

Združene države Amerike - angleščina - NLM (National Library of Medicine)

cardinal health - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 6 mg in 2 ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

astellas pharma us, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenocard (adenosine injection) is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenocard administration. it is important to be sure the adenocard solution actually reaches the systemic circulation (see dosage and administration). adenocard does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenocard administration. intravenous adenocard (adenosine injection) is contraindicated in:

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adenosine, quantity: 6 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - therapeutic indications: adenosine viatris is indicated for the rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications: adenosine viatris is indicated as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine viatris is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be used only when, despite all diagnostic attempts, doubt still persists. adenosine viatris can also be used for improved diagnostic sensitivity of intracavity electrophysiological investigations.